Abstract
Raynaud’s phenomenon (RP) is characterised by sensitivity to cold temperatures associated with either biphasic or uniphasic change in colour of the digits. Since few studies are available which include older adults, the prevalence of RP in the older adult population is estimated from surveys or studies of the general population. The causes of RP in older adults may differ significantly from those in young adults and, therefore, so would the evaluation of RP. Because of comorbities that accompany advancing age, the managment of RP in older adult patients must take into consideration toxicity and adverse reactions that may develop, especially in the frail individual. Although nonpharmacological therapy is preferable, slow-release calcium antagonists provide a relatively well tolerated and effective treatment for moderate to severe RP in older adult patients. Aggressive treatment including hospitalisation is appropriate for older adult patients during periods of critical digital ischaemia associated with RP.
Similar content being viewed by others
References
Belch JJ, Kahn F. Primary Raynaud’s is a disease or disorder: it is not merely a trait. J Rheumatol 1998; 25: 2295–7
Hadler NM. ‘Primary Raynaud’s’ is not a disease or even a disorder; it’s a trait. J Rheumatol 1998; 25: 2291–4
LeRoy EC, Medsger TA. Raynaud’s phenomenon: a proposal for classification. Clin Exp Rheumatol 1992; 10: 485–8
Brennan P, Silman A, Black C, et al. Validity and reliability of three methods used in the diagnosis of Raynaud’s phenomenon: the UK Scleroderma Study Group. Br JRheumatol 1993; 32: 357–61
Wigley FM, Flavahan NA. Raynaud’s phemonenon. Rheum Dis Clin North Am 1996; 22: 765–81
Maricq H, Weinrich MC. Diagnosis of Raynaud’s phenomenon assisted by color charts. J Rheumatol 1988; 15: 4554–9
Gelber A, Wigley F, Stallings R, et al. Raynaud’s phenomenon in a poor, urban, African-American community. Arthritis Rheum 1996; 39 Suppl.: S149
Planchon B, Pistorius A, Beurrier P, et al. Primary Raynaud’s phenomenon: age of onset and pathogenesis in a prospective study of 424 patients. Angiology 1994; 45: 677–86
Fraenkel L, Zyhang YQ, Evans S, et al. The association of estrogen replacement therapy and Raynaud’s phenomena in postmenopausal women. Ann Intern Med 1998; 129: 208–11
Sanchez-Guerrero J, Liang MH, Karlson CW, et al. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med 1995; 122: 430–2
Seibold JR. Scleroderma. In: Kelley WN, Harris ED, Ruddy S, et al., editors. Textbook of rheumatology. 5th ed. Philadelphia: WB Saunders, 1997: 1133–2
Friedman EI, Taylor LM, Porter JM. Late-onset Raynaud’s syndrome: diagnostic and therapeutic considerations. Geriatrics 1988; 43: 59–69
Ling SM, Flynn J, Wigley F. Musculoskeletal diseases. In: Gallo JJ, Busby-Whitehead J, Rabins PV, et al., editors. Reichel’s care of the elderly: clinical aspects of aging. 5th ed. Baltimore (MD): William & Wilkins, 1999
Kellenberg CGM. Overlapping syndromes, undifferentiated connective tissue disease and other fibrosing conditions. Curr Opin Rheumatol 1995; 7: 568–73
Baker SB. Late onset systemic lupus erythematosus. Am J Med 1979; 66: 727–32
Baer AN, Pincus T. Occult systemic lupus erythematosus in elderly men. JAMA 1983; 249: 3350–2
Nesher G, Moore TL, Suckner J. Rheumatoid arthritis in the elderly. J Am Geriatr Soc 1991; 39: 284–94
Grassi W, Blasetti P, Core P, et al. Raynaud’s phenomenon in rheumatoid arthritis. Br J Rheumatol 1994; 33: 139–41
Leppert J, Aberg H, Ringqvist I, et al. Raynaud’s phenomenon in a female population: prevalence and association with other conditions. Angiology 1987; 38: 871–7
Inaba R, Maeda M, Fujita S, et al. Prevalence of Raynaud’s phenomenon and specific clinical signs related to progressive systemic sclerosis in the general population of Japan. Int J Dermatol 1993; 32: 652–5
Allen EV, Brown GE. Raynaud’s disease: a clinical study of 147 cases. JAMA 1932; 183–200
Hines EA, Christensen NA. Raynaud’s disease among men. JAMA 1945; 129: 1–4
Blain A, Coller FA, Carver GB, et al. Raynaud’s disease: a study of criteria for prognosis. Surgery 1951; 29: 387–97
Gifford RW, Hines EA. Raynaud’s disease among women and girls. Circulation 1957; 16: 1012
Nielubowicz J, Zajac S, Szamowskia R, et al. The origin of Raynaud’s phenomenon. J Cardiovasc Surg 1978; 19: 607–14
Gerbracht DD, Steen VD, Ziegler GL, et al. Evolution of primary Raynaud’s phenomenon (Raynaud’s disease) to connective tissue disease. Arthritis Rheum 1985; 28: 87–92
Slater CA, Davis RB, Shmerling RH. Antinuclear antibody testing. Arch Intern Med 1996; 156: 1421–5
Maricq HF, Valter I, Maricq JG. An objective method to estimate the severity of Raynaud phenomenon: digital blood pressure response to cooling. Vasc Med 1998; 3(2): 109–13
Planchon B, De Faucal P, Essboui S, et al. A quantitative test for measuring reactivity to cold by the digital plethsmography technique: application to 66 control subjects and 65 patients with Raynaud’s phenomenon. Angiology 1986; 37(6): 433–9
Friedman RR. Physiologic mechanisms of temperature biofeedback. Biofeedback Self Regul 1991; 16: 95–115
Appiah R, Hiller S, Caspary L, et al. Treatment of primary Raynaud’s syndrome with traditional Chinese acupuncture. J Intern Med 1997; 241: 119–24
Schwartz JB. Clinical pharmacology. In: Hazzard WR, Bierman EL, Blass JP, et al., editors. Principles of geriatric medicine and gerontology. 3rd ed. New York: McGraw-Hill Inc., 1994: 259–76
Tinetti ME, Doucette J, Claus E. The contributions of predisposing and situational risk factors to serious fall injuries. J Am Geriatr Soc 1995; 43: 1207–13
Rodeeheffer RJ, Rommer JA, Wigley F, et al. Controlled double-blind trial of nifedipine in the treatment of Raynaud’s phenomenon. N Engl J Med 1983; 308: 880–3
Winston EL, Pariser KM, Miller KB, et al. Nifedipine as a therapeutic modality for Raynaud’s phenomenon. Arthritis Rheum 1983; 26: 1177–80
Malamet R, Wise RA, Ettinger WH, et al. Nifedipine on the treatment of Raynaud’s phenomenon: evidence for inhibition of platelet activity. Am J Med 1985; 78: 602–8
Gjorup T, Kelback H, Hartling OJ, et al. Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud’s phenomenon. Am Heart J 1986; 111: 742–45
Rhedda A, McCans J, Willan AR, et al. A double-blind placebo controlled crossover randomized trial of diltiazem in Raynaud’s phenomenon. J Rheumatol 1985; 12: 724–7
Wigley FM, Wise RA, Malamet R, et al. Nicardipine in the treatment of Raynaud’s phenomena: dissociation of platelet activation from vasospasm. Arthritis Rheum 1987; 30: 281–6
Challenor VF, Waller DG, Francis DA, et al. Nisoldipine in primary Raynaud’s phenomenon. Eur J Clin Pharmacol 1987; 33: 27–30
Sturgill MG. Seibold JR. Rational use of calcium-channel antagonists in Raynaud’s phenomenon. Curr Opin Rheumatol 1998; 10(6): 584–8
Silvestry FE, Kimmel SE. Calcium-channel blockers in ischemic heart disease. Curr Opin Cardiol 1996; 11: 434–9
Pstay BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first line agents: a systematic review and meta-analysis. JAMA 1997; 277: 739–45
Furberg CD, Psaty BM, Myer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326–31
Pahor M, Guralnik JM, Corti MC, et al. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43: 1191–7
Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure: Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996; 335(15): 1107–14
Janini SD, Scott DGI, Coppock JS, et al. Enalapril in Raynaud’s phenomenon. J Clin Pharm Ther 1988; 13: 145–50
Pancera P, Sansone S, Secchi S, et al. The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud’s phenomenon. J Intern Med 1997; 242(5): 373–6
Neilson SL, Vitting K, Rasmussen K. Prazosin treatment of primary Raynaud’s phenomenon. Eur J Clin Pharmacol 1983; 24: 421–3
Russell IJ, Lessard JA. Prazosin treatment of Raynaud’s phenomenon: a double-blind single crossover study. J Rheumatol 1985; 12: 94–8
Wollersheim H, Thien T, Fennis J, et al. Double-blind, placebo-controlled study of prazosin in Raynaud’s phenomenon. Clin Pharmacol Ther 1986; 40: 219–25
Franks AG. Topical glyceryl trinitrate as adjunctive treatment in Raynaud’s disease. Lancet 1982; I: 76–7
Whitmore SE, Wigley FM, Wise RA. Acute effect of topical minoxidil on digital blood flow in patients with Raynaud’s phenomenon. J Rheumatol 1995; 22: 50–4
Jaffee IA. Serotonin reuptake inhibitors in Raynaud’s phenomena [letter]. Lancet 1995; 345: 1378
Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994; 120: 199–206
Wigley FM, Seibold JR, Wise RA, et al. Intravenous iloprost treatment of Raynaud’s phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992; 1407–14
Wigley FM, Korn JH, Csuka ME, et al. Oral iloprost treatment in patients with Raynaud’s secondary to systemic sclerosis: a multi-center, placebo-controlled double-blind study. Arthritis Rheum 1998; 41: 670–7
Tsukamoto H, Nagasawa K. Successful treatment of Raynaud’s phenomenon with limaprost, an oral prostaglandin E1 analogue [letter]. Br J Rheumatol 1991; 30: 317
Rademaker M, Cooke ED, Almond NE, et al. Comparison of intravenous infusions of iloprost and oral nifedipine in the treatment of Raynaud’s phenomenon in patients with systemic sclerosis: a double-blind randomized study. BMJ 1989; 298: 561–3
Cattral MS, Altraif I, Greig P, et al. Toxic effects of intravenous and oral prostaglandin therapy in patients with liver disease. Am J Med 1994; 97: 369–73
Bunker CB, Reavley C, O’Shaughnessy DJ, et al. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud’s phenomenon. Lancet 1993; 342: 80–3
Bunker CB, Terenghi G, Springall DR, et al. Deficiency of calcitonin gene-related peptide in Raynaud’s phenomenon. Lancet 1990; 336: 1530–3
Khan F, Litchfield SJ, McLaren M, et al. Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud’s phenomenon. Arthritis Rheum 1997; 40: 352–7
Cimminiello C, Milani M, Uberti T, et al. Endothelin, vasoconstriction, and endothelial damage in Raynaud’s phenomenon. Lancet 1991; 337: 114–5
Fritzler MJ, Hart DA. Prolonged improvement of Raynaud’s phenomenon and scleroderma after recombinant tissue plasminogen activator therapy. Arthritis Rheum 1990; 33: 274–6
Gurwitz JH, Gore JM, Goldberg RJ, et al. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Ann Intern Med 1998; 129: 597–604
Simoons ML. Risk-benefit of thrombolysis. Cardiol Clin 1995; 13: 339–45
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ling, S.M., Wigley, F.M. Raynaud’s Phenomenon in Older Adults. Drugs Aging 15, 183–195 (1999). https://doi.org/10.2165/00002512-199915030-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-199915030-00002